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ABSTRACT
Inhibiting the aggregation of amyloid-beta peptide (Aβ) is one therapeutic target for the
prevention and treatment of Alzheimer’s disease. We have previously demonstrated that biphenyl3,3′,4,4′-tetrol (3,4-BPT) effectively abrogates Aβ aggregation at stoichiometric concentrations. To
investigate molecular architecture and determine how the positioning of the hydroxyl hydrogenbond donors impacts inhibitor efficacy, we have synthesized four additional symmetrical
biphenyltetrols (2,3-, 2,4- 2,5- and 3,5-BPT). We have evaluated these inhibitors by means of Congo
red and Thioflavin T dye-binding assays to monitor Aβ aggregation as a function of time and to
determine inhibitor IC50 values for reducing equilibrium levels of aggregation. 2,3- and 2,5-BPT
were observed to be promising inhibitors of Aβ aggregation: we have qualitatively assessed their
IC50 values to be approximately 7X and 3-4X, respectively. In contrast, 2,4- and 3,5-BPT showed
little to no inhibition. Thus, 2,5-BPT was the most successful of the four inhibitors evaluated,
however; it was not as effective as 3,4-BPT, studied previously (IC50 = 1.0 ± 0.3X). The four
isomers we have characterized exhibit a range of IC50 values spanning more than one order of
evaluation of the symmetrical biphenyltetrols, by methods including circular dichroism and
transmission electron microscopy, which will afford greater insight into the Aβ assemblies formed in
the presence and absence of inhibitors. These results will aid in the rational design of additional
small-molecule aggregation inhibitors, including unsymmetrical biphenyltetrols and other
architectures bearing hydroxyl substituents in those positions associated with the greatest inhibitory
efficacy.
INTRODUCTION
Alzheimer’s disease (AD) is currently the sixth-leading cause of death in the United States.1 The
aggregation of amyloid-β (Aβ), a peptide composed of 39-43 amino acids that is formed via proteolytic
cleavage of the amyloid precursor protein (APP), is strongly linked to Alzheimer’s disease (AD).2
Monomeric Aβ self-assembles to form an array of neurotoxic, β-structured aggregates, including soluble
oligomers and insoluble fibrils. The fibrils have received great attention as the primary component of
extracellular senile plaques characteristic of AD brain.3 Research efforts in the last 10-15 years have
shown that smaller Aβ assemblies, specifically soluble oligomers, are more neurotoxic than insoluble
fibrils.4 Therefore, the inhibition of Aβ aggregation is one therapeutic target for the prevention and
treatment of AD.
Previous research has hypothesized that small molecules can be designed and synthesized to
bind to and inhibit the aggregation of Aβ. A number of small molecules containing oxygenated aromatic
rings have demonstrated varying degrees of inhibitory activity.5,6 Reinke and Gestwicki previously
evaluated curcumin (Figure 1) and curcumin-like molecules to identify structural features that are
important for inhibition.7 They identified three major characteristics thought to be necessary for the
inhibition of Aβ aggregation: 1) two aromatic groups, 2) one or more polar, hydrogen bonding
substituents, and 3) a rigid linker of 8-16 Å.7
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Figure 1. Curcumin

To increase understanding of the structure-activity relationship between curcumin-related
molecules and Aβ inhibition, we previously synthesized and evaluated three isomeric
tetrahydroxyterphenyls and a tetrahydroxybiphenyl.8 The terphenyls (3,3”,4,4”-tetrahydroxy-o-terphenyl,
3,3”,4,4”-tetrahydroxy-m-terphenyl, and 3,3”,4,4”-tetrahydroxy-p-terphenyl) were synthesized with the geometry
around the phenyl linker in the ortho- (OTT), meta- (MTT), and para- (PTT) positions, respectively
(Figure 2). These compounds were expected to inhibit Aβ aggregation because they contained two
hydroxy-substituted aromatic groups connected by a rigid linker, in agreement with the structural
features identified by Reinke and Gestwicki.

Figure 2. Representative isomers of terphenyl-3,3",4,4"-tetrol (OTT, MTT, and PTT, respectively)

The biphenyltetrol was synthesized to evaluate the need for the phenyl linker because, according
to Reinke and Gestwicki, the molecule should fail to inhibit Aβ aggregation. All molecules were
evaluated by means of a Congo red assay at a 10X concentration (1X = 25μM). Surprisingly, Stevens and
coworkers concluded that 3,3’,4,4’-biphenyltetrol (3,4-BPT) was the most successful inhibitor with an
IC50 value near 1.0X.8 These researchers suggested that the biphenyltetrol is more conformationally
restricted than the inhibitors that were included in the Reinke and Gestwicki study; therefore, the
characteristics Reinke and Gestwicki associated with inhibitory efficacy may not apply.
3,4-BPT effectively abrogates Aβ aggregation at stoichiometric concentrations. This promising
result inspired us to investigate this molecular architecture and determine how the positioning of
hydroxyl hydrogen-bond donors impacts inhibitor efficacy. Toward that goal, we aimed to synthesize
and evaluate five isomers of 3,4-BPT (Figure 3). The interaction occurring between monomeric Aβ and
BPT is thought to be through hydrogen bonding; however, the mechanism is relatively unknown. The
rearrangement of the hydroxyls around the aromatic rings will aid in determining which positions are
most favorable for inhibition. Currently, we have synthesized and characterized 2,3-, 2,4-, 2,5-, and 3,5BPT. There have been limitations in synthesizing 2,6-BPT, in which steric hindrance is thought to be
preventing the formation of the required intermediate; however, the complete synthesis of 2,6-BPT is
currently in progress.
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Figure 3. Structures of biphenyl-2,2',3,3'-tetrol (2,3-BPT), biphenyl-2,2',4,4'-tetrol (2,4-BPT),
biphenyl-2,2',5,5'-tetrol (2,5-BPT), biphenyl 2,2',6,6'-tetrol (2,6-BPT), biphenyl-3,3',4,4'-tetrol (3,4-BPT), and
biphenyl-3,3',5,5'-tetrol (3,5-BPT), respectively.

The four isomeric compounds were evaluated by means of Thioflavin T and Congo red dyebinding assays. The dyes selectively bind β-sheet structures and allow Aβ aggregation to be monitored as
a function of time for samples with and without inhibitor. We have employed Congo red assays to
determine inhibitor IC50 values and thus quantify the efficacy of the symmetrical molecules. When the
evaluation is complete, we expect to report a range of inhibitor IC50 values that will support our
hypothesis that hydroxyl positioning has a measurable effect on inhibitor activity. These results may
impact the rational design of future inhibitors.

METHODS
Disaggregation of Aβ
Lyophilized Aβ(1-40) peptide was purchased from AnaSpec, Inc. and stored at -20 °C. The
peptide was brought to room temperature and dissolved in hexafluoroisopropnal (HFIP), resulting in a
peptide concentration of 5 mg/mL. The vial was sealed to prevent evaporation loss and remained in a
hood overnight. The following day, HFIP was evaporated under nitrogen for at least 1 hour, leaving
behind a peptide film. The film was dissolved and thoroughly mixed in dimethyl sulfoxide (DMSO) for
20 minutes to obtain a final peptide concentration of 2 mM. Aliquots of the peptide solution were
transferred to microcentrifuge tubes and stored in a -80 °C freezer.
Thioflavin T (ThT) Assay
Aβ(1-40) aliquots in DMSO were brought to room temperature and diluted to 50 μM with 25
mM phosphate buffer solution (25 mM sodium phosphate, 120 mM NaCl, 1.25 µM Thioflavin T, and
0.02% sodium azide, pH 7.4) maintaining 10% DMSO by volume. Inhibitor samples were prepared
similarly with the addition of a biphenyltetrol, 10 mM in DMSO, at varying volumes to obtain the
desired inhibitor concentration (0-500 μM, i.e., 0-10X). Samples with and without inhibitor were
incubated at 37 °C and shaken at 1500 RPM to promote aggregation. Each sample was removed from
the incubator/shaker periodically and loaded into a 1-cm path length quartz cuvette. Fluorescence
spectra were acquired with an excitation wavelength of 450 nm and emission wavelengths of 460-600
nm. Samples were returned to the incubator/shaker and the cuvette was rinsed between samples 3 times
with distilled water. The peak areas from the ThT spectra were integrated and plotted as a percentage of
the control sample as a function of time.
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Congo Red (CR) Assay
Aβ(1-40) aliquots in DMSO were brought to room temperature and diluted to 50 μM with
phosphate buffered saline, (PBS, 1X concentration: 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, and
1.47 mM KH2PO4, pH 7.4) maintaining 10% DMSO by volume. Inhibitor samples were prepared
similarly with the addition of a biphenyltetrol, 10 mM in DMSO, at varying volumes to obtain the
desired inhibitor concentration (0-500 μM, i.e., 0-10X). A CR stock solution of 50 μM was made in 1X
PBS. Samples with and without inhibitor were incubated at 37 °C and shaken at 1500 RPM to promote
aggregation. An aliquot of sample was removed from the incubator/shaker periodically and combined
with an equal volume of 50 μM CR, diluting the CR and A concentrations to 25 μM each. The
CR/sample solution was mixed 20 times to ensure proper association between CR and Aβ and loaded in
a 1-cm path length quartz cuvette; the absorbance was measured at the wavelengths of 403 and 541 nm.
Between samples, the cuvette was rinsed 3 times with a 90% 1X PBS/10% DMSO solution. The
concentrations of bound complex ([CR-Aβ]) for each sample, used to monitor Aβ aggregation, were
calculated from the absorbance values and extinction coefficients at the measured wavelengths,
according to Eq. 1.9 The [CR-A] for each sample was monitored and plotted as a function of time.
[CR-Aβ] = (A541/47,800) - (A403/38,100)
(1)
IC50 Determination
A range of inhibitor concentrations were evaluated to determine the overall inhibitory efficacy of
each biphenyltetrol. Inhibitor samples were prepared as described above, with the desired BPT
concentrations ranging from 25 μM to 500 μM (0.5X-10X). Control and inhibitor samples were
incubated at 37 °C and shaken at 1500 RPM to promote aggregation. When aggregation of the control
reached equilibrium, aliquots of the various inhibitor samples were taken in random order to measure
[CR-Aβ]. Collecting data at equilibrium is favorable for the day-to-day reproducibility of results.
Inhibitor concentrations were quantitatively compared by calculating respective [CR-Aβ] values as a
percent of control. These responses were plotted versus the inhibitor concentration on a semi-log plot.
The IC50 is the concentration at which aggregation is inhibited by 50 %.

RESULTS & DISCUSSION
Our preliminary data from the spectroscopic evaluations of four symmetrical biphenyltetrols
show 2,4- and 3,5-BPT to be poor inhibitors of Aβ aggregation, while 2,3- and 2,5-BPT inhibit
equilibrium levels of aggregation to a quantifiable degree. ThT and CR results were consistent, which
allowed for verification of inhibitor efficacy by two methods and ensured accurate data collection.
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Figure 4. ThT (left) and CR (right) assay results for control vs. 10X 2,4-BPT
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The ThT and CR data for 2,4-BPT at 10X concentration, Figure 4, illustrate the consistency of results
between assays. At equilibrium, there is little difference between the control and 2,4-BPT samples, which
indicates little to no inhibition.
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Figure 5. Congo red assay results for 3,5-BPT (10X concentration, squares) versus inhibitor-free control
(diamonds). At 10X, 3,5-BPT demonstrates little inhibitory activity against Aβ aggregation.

We saw similar results with 3,5-BPT, Figure 5, where there is little difference between the control and
3,5-BPT samples at equilibrium. At 10X concentration, neither 2,4- nor 3,5-BPT demonstrate inhibitory
properties against Aβ aggregation.
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Figure 6. Congo red assay results for 2,3-BPT (10X, squares) versus inhibitor-free control (diamonds). In the
presence of 10X 2,3-BPT, less CR-A complex is formed, indicating some degree of inhibition.

There is a greater difference, at equilibrium, between the control and 10X 2,3-BPT samples which
indicates some degree of inhibition (Figure 6). Similar results were seen with 10X 2,5-BPT in which the
molecule demonstrated inhibitory properties against Aβ aggregation (Figure 7).
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Figure 7. Congo red assay results for 2,5-BPT (10X, squares) show much less CR-A formation compared to
the control (diamonds), which indicates significant inhibition.

We can conclude from our preliminary data that altering the positions of the hydroxyl groups
around the aromatic rings has an effect on inhibitor efficacy. We determined the 2,4- and 3,5- hydroxyl
positions to be unfavorable for inhibition, whereas the 2,3- and 2,5- positions appear to be more
favorable for hydrogen-bonding interactions with Aβ.
As a further evaluation of inhibitor efficacy, we investigated IC50 values for 2,3- and 2,5-BPT.
From preliminary results, we qualitatively determined 2,3- and 2,5-BPT to have IC50 values of about 7X
and 3-4X, respectively. Based on our previous ThT and CR results, the IC50 values of 2,4- and 3,5-BPT
are expected to be greater than 10X. Thus, 2,5-BPT was the most effective inhibitor of the four
molecules evaluated, but it did not match the efficacy of 3,4-BPT, for which the IC50 is 1.0 X.3 The four
isomers we have characterized exhibit a range of IC50 values spanning more than one order of
magnitude, likely due to varying abilities to bind to A assemblies. The range of inhibitory activity
supports our hypothesis that altering positions of the hydroxyl groups affects inhibitor efficacy.
Future work will involve further evaluation of these symmetrical biphenyltetrols, by methods
including circular dichroism and transmission electron microscopy, which will afford greater insight into
the A assemblies formed in the presence and absence of inhibitors. As a result of knowledge gained
from preliminary studies of symmetrical biphenyltetrols, we have also synthesized two unsymmetrical
biphenyltetrols, in which the hydroxyl groups occupy different positions on each ring (Figure 8): a
hybrid of 3,4- and 2,3-BPT (biphenyl-2,3’,4’,3-tetrol, 3,4,2,3-BPT) as well as a hybrid of 3,4- and 2,5-BPT
(biphenyl-2,3’,4’,5-tetrol, 3,4,2,5-BPT). These molecules will allow us to evaluate how the change in
positioning of hydroxyl hydrogen-bond donors around the phenyl rings impacts inhibitor efficacy against
Aβ aggregation.

Figure 8. Structures of biphenyl-2,3’,4’,3-tetrol (3,4,2,3-BPT, left) and biphenyl-2,3’,4’,5-tetrol (3,4,2,5-BPT,
right)

82

REFERENCES
(1) 2013 Alzheimer’s disease facts and figures; Alzheimer’s Association: Chicago, IL, 2013.
(2) Kang, J.; Lemaire, H. G.; Unterbeck, A.; Salbaum, J. M.; Masters, C. L.; Grzeschik, K. H.; Multhaup,
G.; Beyreuther, K.; Muller-Hill, B. The precursor of Alzheimer’s disease amyloid A4 protein
resembles a cell-surface receptor. Nature. 1987, 325, 733-736.
(3) Cras, P.; Kawai, M.; Lowery, D.; Gonzalez-DeWhitt, P.; Greenberg, B.; Perry, G. Senile plaque
neuritis in Alzheimer disease accumulate amyloid precursor protein. Proc. Natl. Acad. Sci. 1991,
88, 7552-7556.
(4) Dahlgren, K. N.; Manelli, A. M.; Stine, W. B.; Baker, L. K.; Krafft, G. A.; LaDu, M. J. Oligomeric and
fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J. Biol. Chem.
2002, 277, 32046-32053.
(5) Churches, Q. I.; Caine, J.; Cavanagh, K.; Epa, V. C.; Waddington, L.; Tranberg, C. E.; Meyer, A. G.;
Varghese, J. N.; Streltsov, V.; Duggan, P. J. Naturally occurring polyphenolic inhibitors of
amyloid beta aggregation. Bioorg. Med. Chem. Lett. 2014, 24, 3108-3112.
(6) Yun, S. L.; Hye, Y. K.; YoungSoo, K.; Jae, H. S.; Eun, J. R.; Hogyu, H.; Kye, J. S. Small molecules
that protect against β-amyloid-induced cytotoxicity by inhibiting aggregation of β-amyloid. Bioorg.
Med. Chem. 2012, 20, 4921-4935.
(7) Reinke, A. A.; Gestwicki, J. E. Structure-activity relationships of amyloid beta-aggregation inhibitors
based of curcumin: Influence of linker length and flexibility. Chem. Biol. Drug. Des. 2007, 70, 206215.
(8) Stevens, C. B.; Hanna, J. M.; Lammi, R. K. Synthesis of tetrahydroxybiphenyls and
tetrahydroxyterphenyls and their evaluation as amyloid-β aggregation inhibitors. Bioorg. Med.
Chem. Lett. 2013, 23, 1703-1706.
(9) Klunk, W. E.; Jacob, R. F.; Mason, R. P. Quantifying amyloid β-peptide (Aβ) aggregation using the
congo red-Aβ (CR-Aβ) spectrophotometric assay. Anal. Biochem. 1999, 266, 66-76.

83

